Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. Show more
Location: Grafenauweg 8, Zug, 6300, Switzerland | Website: https://pharvaris.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.299B
52 Wk Range
$11.51 - $26.33
Previous Close
$23.84
Open
$23.63
Volume
22,887
Day Range
$23.12 - $23.63
Enterprise Value
723.3M
Cash
236.5M
Avg Qtr Burn
-33.59M
Insider Ownership
6.25%
Institutional Own.
89.49%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Deucrictibant immediate-release capsules (PHVS416) Details Hereditary angioedema | Phase 3 Data readout | |
PHVS719 (deucrictibant extended-release tablets) Details Hereditary angioedema | Phase 3 Update | |
PHA121 Details Hereditary angioedema | Phase 2 Interim update |